- Recent immuno-oncology publications further confirm the Galectin Signature in cancer immunotherapy.
- In a rare and important combination of clinical effects, belapectin, Galectin's galectin-3 inhibitor, we believe can both augment ICI or immune agonist therapy while simultaneously improving toxicity/tolerability profiles.
- The NASH landscape has further changed, positioning Galectin for success.
- Belapectin appears to be a bona-fide platform therapy with much therapeutic potential.
- The drug could be worth billions to big pharma.
For further details see:
Galectin Therapeutics: The Galectin Signature - Signed, Sealed, And About To Be Delivered